The settlements by four generic manufacturers in a single Zantac (ranitidine) product liability case gives some sense of what global resolutions might entail. However, brand companies may opt to go to trial rather than settle, as GlaxoSmithKline plc has indicated.
The first trial in the Zantac litigation had been scheduled to begin 22 August in Illinois state court. Counsel for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?